1. Home
  2. PERI vs EDIT Comparison

PERI vs EDIT Comparison

Compare PERI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$8.42

Market Cap

428.3M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.51

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
EDIT
Founded
1999
2013
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
428.3M
432.8M
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
PERI
EDIT
Price
$8.42
$2.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$14.50
$5.30
AVG Volume (30 Days)
600.7K
3.2M
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$9.98
N/A
Revenue Next Year
$2.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$7.63
$1.66
52 Week High
$11.44
$4.54

Technical Indicators

Market Signals
Indicator
PERI
EDIT
Relative Strength Index (RSI) 41.80 41.13
Support Level $8.27 $2.49
Resistance Level $10.43 $2.63
Average True Range (ATR) 0.29 0.35
MACD 0.02 -0.07
Stochastic Oscillator 60.46 8.33

Price Performance

Historical Comparison
PERI
EDIT

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: